1. Home
  2. MMU vs CTNM Comparison

MMU vs CTNM Comparison

Compare MMU & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Managed Municipals Fund Inc.

MMU

Western Asset Managed Municipals Fund Inc.

N/A

Current Price

$10.30

Market Cap

561.5M

Sector

Finance

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$12.35

Market Cap

489.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MMU
CTNM
Founded
1992
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
561.5M
489.4M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
MMU
CTNM
Price
$10.30
$12.35
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
124.6K
175.1K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
4.92%
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.79
$3.57
52 Week High
$10.71
$16.33

Technical Indicators

Market Signals
Indicator
MMU
CTNM
Relative Strength Index (RSI) 55.38 47.44
Support Level $10.24 $11.62
Resistance Level $10.29 $13.26
Average True Range (ATR) 0.08 0.80
MACD 0.02 -0.00
Stochastic Oscillator 69.73 53.28

Price Performance

Historical Comparison
MMU
CTNM

About MMU Western Asset Managed Municipals Fund Inc.

Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: